Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women | Zendy

Sally Hodder | Zendy; Kathleen Squires | Zendy; Cissy Kityo | Zendy; Debbie Hagins | Zendy; Anchalee Avihingsa | Zendy; Anna Kido | Zendy; Shuping Jiang | Zendy; Rima Kulkarni | Zendy; Andrew Cheng | Zendy; Huyen Cao | Zendy

Open Access

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women

Author(s) -

Sally Hodder,

Kathleen Squires,

Cissy Kityo,

Debbie Hagins,

Anchalee Avihingsa,

Anna Kido,

Shuping Jiang,

Rima Kulkarni,

Andrew Cheng,

Huyen Cao

Publication year - 2018

Publication title -

jaids journal of acquired immune deficiency syndromes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.162

H-Index - 157

eISSN - 1944-7884

pISSN - 1525-4135

DOI - 10.1097/qai.0000000000001663

Subject(s) - elvitegravir , cobicistat , tenofovir alafenamide , medicine , tolerability , emtricitabine , regimen , adverse effect , atazanavir , ritonavir , pharmacology , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We investigated the efficacy, safety, and tolerability of switching to a TAF-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and tenofovir alafenamide (E/C/F/TAF) versus remaining on ATV + RTV plus FTC/TDF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research